BioMed Research International

Rare Diseases of the Anterior Segment of the Eye: Update on Diagnosis and Management


Status
Published

1University of Rome “Sapienza”, Rome, Italy

2IRCCS Fondazione GB Bietti, Rome, Italy

3Ospedale San Raffaele, Milan, Italy

4Queen Alexandra Hospital, Portsmouth, UK

5Scheie Eye Institute Philadelphia, Philadelphia, USA


Rare Diseases of the Anterior Segment of the Eye: Update on Diagnosis and Management

Description

The anterior segment of eye is involved in a wide range of rare conditions including, but not limited to, phakomatoses, palpebral malformations, and corneal dystrophies. Appropriate diagnosis and management of these disorders are a requirement to successfully preserve vision and quality of life of patients. Availability of new genetic and instrumental tools, as well as recent discoveries on medical treatment, biotechnology, and cellular therapy, led to an improvement in diagnosis and management of these rare ophthalmic conditions. The deeper knowledge of diagnosis, pathogenic mechanisms, and medical and surgical treatments will allow more targeted therapeutic strategies, hence offering better care to patients.

We invite investigators to submit original research and review articles that will contribute to the definition of the diagnostic criteria, medical and surgical management, and future therapies to treat successfully this seldom encountered group of diseases.

We are particularly interested in articles exploring the current concepts in the diagnosis of rare ocular diseases affecting the anterior segment, advances in molecular genetics and molecular diagnostics, and novel therapeutic approaches including medical, cellular, and surgical treatments.

Potential topics include, but are not limited to:

  • Congenital palpebral abnormalities
  • Congenital cornea diseases
  • Corneal dystrophies
  • Iridocorneal endothelial (ICE) syndrome
  • Congenital glaucoma
  • Phakomatosis with eye involvement
BioMed Research International
 Journal metrics
Acceptance rate30%
Submission to final decision69 days
Acceptance to publication36 days
CiteScore2.410
Impact Factor2.197
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.